Hans Jaeger

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

Edgar T. Overton, Gary Richmond, Giuliano Rizzardini et al. · The Lancet · 2020 · 364 citations

Pharmacy, Pharmacology, Pharmacotherapy +15

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

Hans Jaeger, Edgar T. Overton, Gary Richmond et al. · The Lancet HIV · 2021 · 135 citations

Pharmacy, Pharmacology, Pharmacotherapy +15

Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma

Christian Hoffmann, Eva Wolf, Gerd Fätkenheuer et al. · AIDS · 2003 · 123 citations

Medicine, Infectious Diseases, Oncology +14

Generations in History: Reflections on a Controversial Concept

Hans Jaeger · History and Theory · 1985 · 102 citations

Humanities, History, Historiography +11

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial

Jean‐Michel Molina, Kathleen Squires, Paul E. Sax et al. · The Lancet HIV · 2019 · 96 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +10